Stock Movers Compass Pathways, Masimo Spike; General Mills Falls
Feb 17, 2026
Avalon Purnell, Bloomberg equities reporter covering stocks like Compass Pathways and Masimo. She discusses Compass Pathways' psilocybin trial news and Masimo’s takeover by Danaher. They also touch on NVIDIA's chip demand from Meta and General Mills' lowered forecast.
AI Snips
Chapters
Transcript
Episode notes
Psilocybin Trial Breakthrough
- Compass Pathways' psilocybin therapy hit key trial endpoints, signaling progress in psychedelic mental-health treatments.
- The result reduces uncertainty but the company still faces regulatory hoops with the FDA before commercialization.
Clinician Endorsement From A Friend
- Tim Stenovec shared a personal connection: a nurse-turned-nurse-practitioner who focuses on psychedelic mental-health treatments and endorses them.
- The anecdote illustrates clinician enthusiasm and real-world adoption among some providers.
M&A Spurs Big Stock Move
- Masimo jumped after Danaher agreed to acquire it for $180 per share, highlighting M&A as a major catalyst for sudden stock moves.
- Analysts view the deal as Danaher's strategic shift toward med tech to diversify from diagnostics and stabilize revenue.